Working… Menu

Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00334048
Recruitment Status : Completed
First Posted : June 6, 2006
Last Update Posted : February 19, 2015
Information provided by:
St. Luke's-Roosevelt Hospital Center

Brief Summary:
Antidepressant medicines sometimes cause sexual side effects. The purpose of this study is to determine whether the sexual dysfunction sometimes caused by selective serotonin reuptake inhibitor (SSRI) antidepressant medications can be reversed by treatment with Requip (ropinirole), a medicine which is used to treat Parkinson's Disease and restless leg syndrome.

Condition or disease Intervention/treatment Phase
Sexual Dysfunction Drug: Ropinirole (Requip) Phase 4

Detailed Description:

A significant proportion of patients taking pharmacotherapy for treatment of depression experience sexual dysfunction at distressing levels, with reported rates varying considerably. When sexual dysfunction is assessed prospectively using structured questionnaires, high levels of dysfunction have been found. SSRIs including paroxetine, sertraline, and other medications, have been shown to have a similar frequency of sexual side effects and in a recent prospectively designed study 50% of men taking sertraline reported that they were only "slightly" (18%) or "not at all" (32%) satisfied with their sexual functioning. It is reported that sexual side effects of antidepressant treatment frequently result in noncompliance with and/or premature discontinuation of treatment. A recent study showed that the dopamine agonist Requip (Ropinirole) reduced the amount of SSRI-associated sexual dysfunction. The proposed study will utilize a placebo control group in a crossover design to determine the effect on sexual dysfunction of adding Requip (Requip CR formulation) to the patient's SSRI treatment.

30 patients experiencing sexual dysfunction attributable to SSRI treatment for depression will be entered into this study. All patients will receive 6 weeks of treatment with Ropinirole and 6 weeks with placebo in a crossover fashion. Assessments of sexual functioning and depression will be made at each visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Treatment of Sexual Dysfunction Secondary to Antidepressant Pharmacotherapy: A Double-blind Comparison of Requip (Ropinirole) vs. Placebo in Patients Taking SSRI Antidepressants
Study Start Date : June 2006
Actual Primary Completion Date : September 2007
Actual Study Completion Date : September 2007

Resource links provided by the National Library of Medicine

Intervention Details:
  • Drug: Ropinirole (Requip)
    1 mg extended release formulation given once per day to a maximum of 4 per day
    Other Name: requip, ropinirole, requip XL

Primary Outcome Measures :
  1. International Index of Erectile Function (IIEF) [ Time Frame: 6 weeks ]
  2. Sexual Function and Satisfaction Questionnaire (SFSQ) [ Time Frame: 6 weeks ]

Secondary Outcome Measures :
  1. Hamilton Depression Rating Scale, 17 items (HDRS-17) [ Time Frame: 6 weeks ]
  2. Global Assessment of Functioning Scale (GAFS) [ Time Frame: 6 weeks ]
  3. Clinical Global Impressions (CGI) [ Time Frame: 6 weeks ]
  4. CGI-Sexual functioning (CGI-Sx) [ Time Frame: 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. male or female outpatients 18-65 years old
  2. currently taking fluoxetine, sertraline, paroxetine, citalopram, or escitalopram at a stable dosage within the ranges specified for 1 month or longer required dosage range: (Prozac (fluoxetine) 20-80 mg/day; Celexa (citalopram) 20-60 mg/day; Lexapro (escitalopram) 10-30 mg/day; Zoloft (sertraline) 50-200 mg/day; Paxil (paroxetine) 20-60 mg/day; Paxil CR (paroxetine CR) 25-75 mg/day
  3. Currently responding to the SSRI antidepressant treatment, as indicated by

    • a score of 15 or less on the HDRS 24 item at screening and baseline, and (b) CGI-Severity score of 2 or less at baseline
  4. Meets DSM-IV criteria for Substance-Induced Sexual Dysfunction, with impairment of desire, arousal, or orgasm
  5. Are currently involved in an intimate relationship which includes sexual contact
  6. agree to use double-barrier contraception during sexual intercourse during the course of the study (women only)
  7. Agree to the study team contacting the physician who prescribe their SSRI medication to inform them of their participation in the current study

Exclusion Criteria:

  1. Patients with a DSM-IV diagnosis of Delirium, Dementia, and Amnestic, and other Cognitive Disorders,
  2. Patients with a principal diagnosis meeting DSM-IV criteria for: Bipolar Disorder or cyclothymia, Schizophrenia, Delusional (Paranoid) Disorders and Psychotic Disorders Not Otherwise Specified, or Anorexia Nervosa or Bulimia,
  3. Patients who, within the past 6 months, met DSM-IV criteria for abuse of or dependence on any drug, including alcohol,
  4. Patients who would pose a serious risk for suicide during the course of the study, as evidenced by one of the following:

    • report of having a specific plan for killing themselves,
    • a score of 3 or higher on the Hamilton Depression Rating Scale item 3 as rated by the study doctor at the first visit, (indicative of active suicidal thoughts or behaviors), or
    • a suicide attempt within the past 6 months,
  5. Patients with a history of medical conditions or procedures which may cause sexual dysfunction, including: peripheral vascular disease, radical prostatectomy, trans-urethral resection of the prostate [TURP], or spinal cord injury.
  6. History of sexual dysfunction predating onset of depression and/or initiation of antidepressant therapy,
  7. Patients receiving any other treatment for sexual dysfunction, including sex therapy
  8. Pregnant or nursing women.
  9. Patients with unstable or life-threatening medical conditions, such as uncontrolled hypertension, diabetes, or hypothyroidism, acute infections, pneumonia, severe renal or hepatic impairment.
  10. Patients with any the following: retinal disease, sleep apnea, or narcolepsy.
  11. Patients taking dopamine agonist medication.
  12. Patients taking medications that are

    • associated with orthostatic hypotension, such as tricyclic antidepressants, MAO Inhibitors, and alpha1 antagonists
    • CYP1A2 inhibitors, such as fluoroquinolones, fluvoxamine, cimetidine
    • SSRI medication used cyclically for PMDD
  13. Patients who do not expect to have regular sexual contact with another person over the next 13 weeks.
  14. Patients with a DSM-IV diagnosis of Pathological Gambling

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00334048

Layout table for location information
United States, New York
Mood Disorders Research Program
New York, New York, United States, 10019
Sponsors and Collaborators
St. Luke's-Roosevelt Hospital Center
Layout table for investigator information
Principal Investigator: David J. Hellerstein, MD St. Luke's Roosevelt Hospital Center and NY State Psychiatric Institute
Additional Information:
Layout table for additonal information
Responsible Party: David J. Hellerstein, MD, NY State Psychiatric Institute Identifier: NCT00334048    
Other Study ID Numbers: 06-036
First Posted: June 6, 2006    Key Record Dates
Last Update Posted: February 19, 2015
Last Verified: February 2015
Keywords provided by St. Luke's-Roosevelt Hospital Center:
Medication-induced sexual dysfunction
SSRI-induced sexual dysfunction
Delayed ejaculation
Sexual dysfunction
Antidepressant-induced sexual dysfunction
Dopamine agonist
Serotonin reuptake inhibitor
Sexual dysfunction, physiological, medication-induced
Additional relevant MeSH terms:
Layout table for MeSH terms
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs